US - HealthQuill

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

by HealthQuill
October 28, 2024
0 Comments

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

by HealthQuill
October 28, 2024
0 Comments

GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to make sterile liquid vaccines and medicines as demand grows.

Drugs Health Pharma

GSK to invest $800 million in US to double capacity at Marietta facility

GSK Plc., will invest $800 million in its manufacturing facility in the US — the largest investment to date in the country — to.

by HealthQuill
October 27, 2024
0 Comments

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy medicine in a trial, according to a statement.

Drugs Health Pharma

Novo’s type 2 oral diabetic drug cuts heart diseases by 14% in a trial

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.

by HealthQuill
October 21, 2024
0 Comments

Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.

Drugs Health Pharma

Astellas Pharma gets US regulator’s nod for its gastric cancer drug

Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.

by HealthQuill
October 21, 2024
0 Comments

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to extend the lives of patients who had undergone prior treatments.

Drugs Health Pharma

Gilead’s end-stage confirmatory trials of bladder cancer drug fail

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.

by HealthQuill
October 21, 2024
0 Comments

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug to treat seizures in a group of rare epilepsies.

Drugs Health Pharma

Lundbeck targets epileptic drug, to buy Longboard for $2.6 billion

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug.

by HealthQuill
October 14, 2024
0 Comments

US-based Baxter International Inc., is implementing an allocation policy to limit stockpiling of its drugs after Hurricane Helene ripped through its facility in North Carolina.

Climate Drugs Medical

Baxter plans to limit stockpiling of its drugs after Hurricane Helene

US-based Baxter International Inc., is implementing an allocation policy to limit stockpiling of its drugs after Hurricane Helene ripped through its facility in.